Drug Trial Radar · NCT04613999
A Study of Ralinepag in Healthy Chinese Adult Subjects
Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Oct 9, 2020
Primary completion
Nov 9, 2020
Study completion Nov 9, 2020
Sponsor
- Lead sponsor
- Everstar Medicines (Shanghai) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1 Open-label, Non-randomized, Single Ascending Dose Escalation Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Ralinepag Extended Release (XR) Tablet Formulation In Healthy Chinese Subjects.
Conditions
- Healthy Volunteer
- Pharmacokinetic Study
Interventions
RalinepagDrug
Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration. It is planned that every subject will receive each of the following regimens in the fasted state: * Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet * Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets * Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Baseline to 96 hours
- TmaxTime frame: Baseline to 96 hours
- T1/2Time frame: Baseline to 96 hours
- AUC0-24Time frame: Baseline to 96 hours
- AUClastTime frame: Baseline to 96 hours
- AUCinfTime frame: Baseline to 96 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.